Acceleron Pharma Stock Forecast, Price & News

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

Is Acceleron Pharma a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Acceleron Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XLRN, but not buy additional shares or sell existing shares.
View analyst ratings for Acceleron Pharma or view top-rated stocks.

How has Acceleron Pharma's stock been impacted by Coronavirus?

Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XLRN stock has increased by 111.8% and is now trading at $178.75.
View which stocks have been most impacted by COVID-19.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Acceleron Pharma.

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.98) by $0.18. The biopharmaceutical company had revenue of $34.20 million for the quarter, compared to analyst estimates of $35.39 million. Acceleron Pharma had a negative net margin of 226.01% and a negative trailing twelve-month return on equity of 32.11%. The company's quarterly revenue was up 51.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.66) earnings per share.
View Acceleron Pharma's earnings history.

What price target have analysts set for XLRN?

14 equities research analysts have issued 12-month price targets for Acceleron Pharma's shares. Their forecasts range from $132.00 to $183.00. On average, they expect Acceleron Pharma's stock price to reach $171.29 in the next year. This suggests that the stock has a possible downside of 4.2%.
View analysts' price targets for Acceleron Pharma or view top-rated stocks among Wall Street analysts.

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the following people:

• Habib J. Dable, President, Chief Executive Officer & Director (LinkedIn Profile)
• Lisa Wyman, Vice President-Operations
• Kevin F. McLaughlin, Chief Financial Officer, Treasurer & Senior VP (LinkedIn Profile)
• Ravindra Kumar, Chief Scientific Officer & Senior Vice President
• Jay T. Backstrom, Executive VP & Head-Research & Development

What is Habib Dable's approval rating as Acceleron Pharma's CEO?

11 employees have rated Acceleron Pharma CEO Habib Dable on Glassdoor.com. Habib Dable has an approval rating of 100% among Acceleron Pharma's employees. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Acceleron Pharma's key competitors?

Some companies that are related to Acceleron Pharma include Biogen (BIIB), Seagen (SGEN), Bio-Techne (TECH), Novozymes A/S (NVZMY), Repligen (RGEN), Novavax (NVAX), argenx (ARGX), QIAGEN (QGEN), Neurocrine Biosciences (NBIX), Vir Biotechnology (VIR), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Exelixis (EXEL) and Fate Therapeutics (FATE).
View all of XLRN's competitors.

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN).

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.50%), Farallon Capital Management LLC (3.54%), Janus Henderson Group PLC (2.61%), Bamco Inc. NY (2.11%), Artal Group S.A. (1.64%) and Magnetar Financial LLC (1.36%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Sujay Kango, Terrence C Kearney and Thomas A Mccourt.
View institutional ownership trends for Acceleron Pharma.

Which major investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Artisan Partners Limited Partnership, BlackRock Inc., Artal Group S.A., Farallon Capital Management LLC, Carmignac Gestion, Janus Henderson Group PLC, and Rhenman & Partners Asset Management AB. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Joseph S Zakrzewski, Kevin F Mclaughlin, Sujay Kango, and Thomas A Mccourt.
View insider buying and selling activity for Acceleron Pharma or view top insider-selling stocks.

Which major investors are buying Acceleron Pharma stock?

XLRN stock was acquired by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Versor Investments LP, Alpine Associates Management Inc., Goldman Sachs Group Inc., Jane Street Group LLC, Citigroup Inc., Millennium Management LLC, and Westchester Capital Management LLC.
View insider buying and selling activity for Acceleron Pharma or or view top insider-buying stocks.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $178.75.

How much money does Acceleron Pharma make?

Acceleron Pharma has a market capitalization of $10.93 billion and generates $92.52 million in revenue each year. The biopharmaceutical company earns $-166.03 million in net income (profit) each year or ($4.21) on an earnings per share basis.

How many employees does Acceleron Pharma have?

Acceleron Pharma employs 312 workers across the globe.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is www.acceleronpharma.com.

Where are Acceleron Pharma's headquarters?

Acceleron Pharma is headquartered at 128 SYDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at (617) 649-9200, via email at [email protected], or via fax at 617-649-9988.